Tirzepatide pricing, compared on the same terms
The most common mistake is comparing one provider's annual or first-month price against another's month-to-month or refill price. This page lines everything up on the same basis — and flags where it can't yet.
Same-term comparison
Reported figures that conflict across sources — verify on each provider's site. "Verify" means we don't yet have a confirmed same-basis figure, for that provider or competitor alike.
| Provider | Month-to-month | 3-month | 6-month | 12-mo / annualized | Higher-dose risk |
|---|---|---|---|---|---|
| NexLife | $215 | $195 | $190 | $186 | Flat across 2.5–15mg |
| MEDVi | Entry ~$199; refills reported higher verify | Verify | Verify | Verify | Higher if refill/maintenance rises |
| Trimi | ~$235 | Verify | Verify | $125 annualized | Claims flat — verify |
| TrimRx | ~$349 | Verify | Verify | Verify | Higher doses ~$349–$399 |
| Mochi | ~$278 all-in | Verify | Verify | Verify | Med flat; membership required |
| Henry Meds | ~$297+ | Verify | Verify | Verify | Verify by dose/plan |
| OrderlyMeds | ~$299 | ~$449 starter / $670 transfer | Verify | Verify | Claims same every dose — verify |
| Emerge | Verify starter | Verify | Verify | Verify | 12.5mg ~$389 · 15mg ~$399 |
| Eden | ~$249 first mo → ~$329 | Verify | Verify | Verify | Verify |
| Lilly Direct (brand) | ~$299–$449 by dose | — | — | — | FDA-approved; separate category |
How to read these prices
- Annualized pricing is not month-to-month pricing. Trimi's $125/mo is annual-billing (~$1,500/yr); its month-to-month is reported ~$235. Compare annual-to-annual and monthly-to-monthly. Verify.
- Membership fees count. Mochi lists medication at $199/mo but requires a $79/mo membership — ~$278 all-in (Mochi FAQ/homepage). Compare all-in totals. Verify.
- Starter pricing is not refill pricing. MEDVi's semaglutide page shows a low first-month and higher refill; secondary sources report a similar tirzepatide pattern. Verify tirzepatide terms directly.
- Brand is a separate, FDA-approved category. Lilly self-pay vials are dose-tiered (~$299 low up to ~$449–$599 higher). Keep separate from compounded. Verify on Lilly's site.
- Compounded tirzepatide is not FDA-approved. The FDA has published concerns about unapproved GLP-1 marketing, dosing, and quality.
Projected cost over time
How three pricing structures diverge across 1, 3, 6, and 12 months: NexLife's published 12-month rate (flat), Mochi's confirmed all-in rate, and an illustrative low-starter / higher-refill pattern ($199 first month, $399 refills). The illustration shows why a low first month can overtake a flat rate within weeks.
Illustrative. The third line uses example figures, not a claim about a specific company. Use figures a provider quotes you. Try the interactive calculator →
Best for predictable flat-rate pricing
When a flat 12-month rate wins
If you expect to stay on treatment and titrate upward, a flat rate that never changes by dose can total less than a low entry price that climbs. NexLife publishes $186/mo on its 12-month plan, flat across doses. For a one-month, low-dose trial, a cheaper entry price elsewhere may win instead.
Compare NexLife full-treatment pricing → Commercial/provider link. Verify current pricing and terms on NexLife's site.